Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Burge

Showing results (181-190 of 190) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 190 results.
Internal Medicine Journal|November 19, 2014
Treatment and outcomes of metastatic colorectal cancer in Australia: defining differences between public and private practiceK Field, J Shapiro, H-L Wong, et al.
British Journal of Cancer|August 25, 2010
Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agentJ D Lickliter, A B Francesconi, G Smith, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2023
HMGB1 acts as an agent of host defense at the gut mucosal barrierA-M C Overstreet, B Anderson, M Burge, et al.
BMC Cancer|March 16, 2022
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinomaR Mercieca-Bebber, E H Barnes, K Wilson, et al.
Cancer Treatment and Research Communications|June 17, 2024
Early onset metastatic colorectal cancer in AustraliaA Jalali, S Smith, G Kim, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Real-world characteristics and outcomes of patients with BRAF<sup>V600E</sup>-mutant metastatic colorectal cancer in Australia: the COALA projectN Hitchen, H-L Wong, R Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 29, 2019
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancerB Lee, L Lipton, J Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trialA P Barbour, E T Walpole, G T Mai, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, multicentre, real-world analysisS Banks, W Hong, K Degeling, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trialJ Lee, A Dean, T Price, et al.
Pageof 19

Showing results (181-190 of 190) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 190 results.
Internal Medicine Journal|November 19, 2014
Treatment and outcomes of metastatic colorectal cancer in Australia: defining differences between public and private practiceK Field, J Shapiro, H-L Wong, et al.
British Journal of Cancer|August 25, 2010
Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agentJ D Lickliter, A B Francesconi, G Smith, et al.
Biorxiv : the Preprint Server for Biology|July 3, 2023
HMGB1 acts as an agent of host defense at the gut mucosal barrierA-M C Overstreet, B Anderson, M Burge, et al.
BMC Cancer|March 16, 2022
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: a randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinomaR Mercieca-Bebber, E H Barnes, K Wilson, et al.
Cancer Treatment and Research Communications|June 17, 2024
Early onset metastatic colorectal cancer in AustraliaA Jalali, S Smith, G Kim, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Real-world characteristics and outcomes of patients with BRAF<sup>V600E</sup>-mutant metastatic colorectal cancer in Australia: the COALA projectN Hitchen, H-L Wong, R Wong, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 29, 2019
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancerB Lee, L Lipton, J Cohen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 22, 2020
Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II trialA P Barbour, E T Walpole, G T Mai, et al.
ESMO Real World Data and Digital Oncology|February 6, 2026
Impact of neoadjuvant FOLFIRINOX over upfront resection in borderline resectable pancreatic cancer-an international, multicentre, real-world analysisS Banks, W Hong, K Degeling, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
ASCEND: a randomised, double-blinded, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel with LSTA1 in untreated metastatic pancreatic adenocarcinoma. An Australasian Gastro-Intestinal Trials Group (AGITG) trialJ Lee, A Dean, T Price, et al.
Pageof 19